Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;9(3):635-8.
doi: 10.1007/s13311-012-0121-1.

Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor

Affiliations

Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor

Fatta B Nahab et al. Neurotherapeutics. 2012 Jul.

Abstract

Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent. We used an established harmaline-based mouse model of ET to compare tremor suppression by 1-octanol and octanoic acid. The dose-related effect on digitized motion power within the tremor bandwidth as a fraction of overall motion power was analyzed. Both 1-octanol and octanoic acid provided significant reductions in harmaline tremor. An 8-carbon alkyl alcohol and carboxylic acid each suppress tremor in a pre-clinical mouse model of ET. Further studies are warranted to determine the safety and efficacy of such agents in humans with ET.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean motion power percentage of harmaline-injected mice treated with octanoic acid or 1-octanol at 10-70 minutes following treatment. For comparison, pre-harmaline baseline (B) and pre-treatment harmaline (H) epochs are shown for each drug, averaged across all treatment groups. The motion power percentage refers to digitized motion power within the tremor bandwidth (10-16 Hz) divided by overall motion power at 0-34 Hz. Means and SEMs are shown. Statistical comparisons are with 0 mg/kg and Student’s t-test. *p < 0.05, **p = 0.01, ***p < 0.001

References

    1. Elble R, Deuschl G. Milestones in tremor research. Mov Disord. 2011;26:1096–1105. doi: 10.1002/mds.23579. - DOI - PubMed
    1. Paris-Robidas S, Brochu E, Sintes M, et al. Defective dentate nucleus GABA receptors in essential tremor. Brain. 2012;135:105–116. doi: 10.1093/brain/awr301. - DOI - PubMed
    1. Boecker H, Weindl A, Brooks DJ, et al. GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J Nucl Med. 2010;51:1030–1035. doi: 10.2967/jnumed.109.074120. - DOI - PubMed
    1. Zesiewicz TA, Elble R, Louis ED, et al. Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2011;77:1752–1755. doi: 10.1212/WNL.0b013e318236f0fd. - DOI - PMC - PubMed
    1. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10:148–161. doi: 10.1016/S1474-4422(10)70322-7. - DOI - PubMed

Publication types